Randomized trial · people

Enicepatide: -4.7% to -8.0% body weight change by day 29 in phase 1

Checked against the paper Randomized trialPublished by PepVault

The takeaway

This is an early human result for enicepatide: weight loss and better blood sugar over 4 weeks, with side effects similar to other drugs in its class.

Kind
Randomized trial
Studied in
People
Published
2026
Journal
Mol Metab

What they tested

The team wanted to know whether enicepatide (CT-388), a weekly shot that acts on both the GLP-1 and GIP receptors, improves weight loss and blood sugar control in people as it did in lab models.

How the study was done

This was a phase 1, double-blind, randomized, placebo-controlled trial (placebo is a dummy shot) in otherwise healthy adults with overweight or obesity. Participants got either single shots under the skin (0.5-7.5 mg) or 4 weekly shots (5-12 mg). The paper also included cell tests and studies in mice and monkeys.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking enicepatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

In people, mean body weight changed by -4.7% to -8.0% from the start to day 29 across the enicepatide doses, compared with -0.5% on placebo. Blood sugar measures improved both while fasting and during an oral glucose tolerance test, a test of how the body handles a sugary drink. Most side effects were mild or moderate, and the safety pattern matched other incretin-based medicines. In mice, the compound lowered body weight, reduced appetite and improved MASH pathology (MASH is a fatty liver disease with inflammation), and it improved blood sugar control in both mice and monkeys.

What it doesn’t show

This was an early, short trial of about 4 weeks in otherwise healthy people, so it can't show longer-term weight loss or how the drug works in people with type 2 diabetes. The liver and appetite results came from mice, not people.

The paper

Chakravarthy et al. Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity. Mol Metab. 2026.

The compound

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking enicepatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo